| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.28 | 6e-05 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.0006 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.0007 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.073 | 0.02 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |